LOS ANGELES, CA — New research says smoking marijuana may be less likely to cause bladder cancer than smoking cigarettes.
For the study, the researchers compared the risk of bladder cancer in more than 83,000 men who smoked cigarettes only, marijuana (cannabis) only, or both substances. The investigators found that men who only smoked pot were the least likely to develop bladder cancer over the course of 11 years.
“Cannabis use only was associated with a 45 percent reduction in bladder cancer incidence, and tobacco use only was associated with a 52 percent increase in bladder cancer,” said study author Dr. Anil A. Thomas, a fellow in urology at Kaiser Permanente Medical Center in Los Angeles.
Smoking both tobacco and marijuana raised the risk of bladder cancer, but less so than for those who only smoked tobacco, Thomas found. He presented the findings Monday at the American Urological Association annual meeting in San Diego.
Dr. Karim Chamie, an assistant professor of urology at the David Geffen School of Medicine at the University of California, Los Angeles, took issue with the fact that every man in the study smoked something, so there was no comparison to men who did not smoke at all.
“It’s hard to judge a study when the referenc. . . . . READ MORE
LOS ANGELES, CA — In a recent presentation given at the annual meeting of the American Association of Cancer Research, investigators from the University of California, Los Angeles provided the latest data reaffirming that cannabis consumption is not associated with an elevated risk of lung cancer.
Below is a summary of the findings from The Oncology Report:
The study included data from six case-control studies conducted from 1999 to 2012 in the United States, Canada, the United Kingdom, and New Zealand, with a subject pool of 2,159 lung cancer cases and 2,985 controls. All of the studies were part of the International Lung Cancer Consortium (ILCCO), an international group of lung cancer researchers with the aim of sharing comparable data from ongoing and recently completed lung cancer studies from different geographical areas and ethnicities.
Dr. Zhang of the University of California, Los Angeles, performed two analyses. One compared all lung cancer cases and all controls, regardless of concurrent or past tobacco use. Then, to reduce confounding by tobacco,. . . . . READ MORE
PHILADELPHIA, PA — The administration of synthetic cannabinoid agonists limits HIV infection in macrophages (white blood cells that aid in the body’s immune response), according to preclinical data published in the Journal of Leukocyte Biology. Macrophages are one of the first type of cells infected by the HIV virus when it enters the body.
Investigators at Temple University School of Medicine in Philadelphia assessed the impact of three commercially available synthetic THC agonists on HIV-infected macrophage cells.
Following administration, researchers sampled the cells periodically to measure the activity of an enzyme called reverse transcriptase (RT), which is essential for HIV replication. By day 7, investigators reported that the administration of all three compounds was associated with a significant decreased in HIV replication.
Stated a Temple University Health System press release: “The results suggest that selective CB2 (cannabinoid 2 receptor) agonists could potentially be used in tandem with existing antiretroviral drugs,. . . . . READ MORE